Synergy CHC Reports $12.3M Net Loss, Material Weaknesses, and Critical Customer Order Reductions Amidst Debt Restructuring and Dilutive Financing
summarizeSummary
Synergy CHC Corp. reported a substantial net loss of $12.34 million for fiscal 2025, disclosed material weaknesses in internal controls, and revealed a major customer (Costco) is significantly reducing orders, all while navigating complex debt restructuring and mandatory dilutive equity raises.
check_boxKey Events
-
Significant Financial Decline in 2025
The company reported a net loss of $12,341,208 for fiscal year 2025, a sharp decline from a net income of $2,124,976 in 2024. Revenue decreased by $4.45 million to $30.38 million, and EBITDA swung from a positive $6.46 million in 2024 to a negative $6.19 million in 2025.
-
Material Weaknesses in Internal Controls
Management identified material weaknesses in the implementation of segregation of duties and clearly defined roles within its finance and accounting functions, concluding that internal control over financial reporting was not effective as of December 31, 2025.
-
Going Concern Uncertainty Addressed
Despite an accumulated deficit of $56.44 million and significant cash usage in operations, management concluded that factors such as a working capital surplus, $3.7 million in capital raised in 2025, debt restructuring, layoffs, and an established ATM program alleviate substantial doubt about the company's ability to continue as a going concern.
-
Mandatory Equity Raise and Dilutive Warrants
A second amendment to the term loan agreement (March 24, 2026) mandates a $10 million equity raise by September 30, 2026, with a 2.00% interest rate increase penalty for non-compliance. In connection, a Lender Warrant was issued for 3,000,000 shares at a nominal exercise price of $0.00001, exercisable upon a 'Qualified Event of Default' and subject to shareholder approval for full exercise.
auto_awesomeAnalysis
Synergy CHC Corp.'s 2025 annual report reveals a company in significant financial distress, marked by a substantial net loss and negative EBITDA, a sharp reversal from the previous year's profit. The disclosure of material weaknesses in internal controls over financial reporting is a serious governance concern, indicating a lack of robust financial oversight. While management states that going concern doubts are alleviated by debt restructuring, layoffs, and capital raises, the underlying financial performance and operational challenges remain severe. The mandatory $10 million equity raise by September 2026, coupled with the issuance of dilutive warrants and a major customer (Costco) significantly reducing orders due to declining sales, highlights the precarious financial position and operational headwinds. Investors should be highly cautious, as the company faces ongoing dilution, significant customer concentration risk, and a challenging path to profitability.
At the time of this filing, SNYR was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.5M. The 52-week trading range was $0.99 to $4.08. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.